Report
Rune Majlund Dahl
EUR 95.03 For Business Accounts Only

Novo Nordisk (Buy, TP: DKK1150.00) - Consensus Wegovy sales aligning

We are just below consensus on Q3e LCY sales growth, reflecting our lower Wegovy and Ozempic sales, we believe due to some contributors lacking US prescription data, or differences in rebate assumptions (we see limited risk of Q3 wholesale inventory reductions). We expect management to narrow the 2024 guidance for YOY LCY sales growth to 24–28% (from 22–28%) and LCY operating profit growth of 22–28% (20–28%). We reiterate our BUY and DKK1,150 target price.
Underlying
Novo Nordisk A/S Class B

Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Rune Majlund Dahl

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch